Cardiff Oncology Inc (NASDAQ: CRDF) on Monday, plunged -4.92% from the previous trading day, before settling in for the closing price of $2.64. Within the past 52 weeks, CRDF’s price has moved between $2.01 and $5.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 19.36% annually for the last half of the decade. The company achieved an average annual earnings per share of 12.37%. With a float of $60.47 million, this company’s outstanding shares have now reached $66.53 million.
In an organization with 33 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.41%, operating margin of -12784.0%, and the pretax margin is -12007.29%.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cardiff Oncology Inc is 9.11%, while institutional ownership is 43.94%. The most recent insider transaction that took place on Jul 30 ’25, was worth 673,750. In this transaction Director of this company bought 275,000 shares at a rate of $2.45, taking the stock ownership to the 1,330,676 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 15,000 for $2.45, making the entire transaction worth $36,750. This insider now owns 1,345,676 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.08% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Cardiff Oncology Inc (CRDF) is currently performing well based on its current performance indicators. A quick ratio of 4.42 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 303.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Let’s dig in a bit further. During the last 5-days, its volume was 7.61 million. That was better than the volume of 1.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.90%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 8.91%, which indicates a significant increase from 8.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.37 in the past 14 days, which was higher than the 0.25 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.57, while its 200-day Moving Average is $3.45.
